A compound of formula: ##STR00001##
or its pharmaceutically acceptable salt. L is NR.sup.2R.sup.3, SR.sup.7, SO.sub.2R.sup.8, alkyl, or alkenyl; R.sup.2 is hydrogen, alkyl, alkenyl, or alkynyl; R.sup.3 is hydrogen, alkyl, alkenyl, alkynyl; R.sup.7 is hydrogen, alkyl, alkenyl, or alkynyl; R.sup.8 is hydrogen, alkyl, alkenyl, or alkynyl, provided that R.sup.8 is not unsubstituted methyl or trifluoromethyl; Y is alkyl, alkenyl, alkynyl, aryl, provided that Y is not unsubstituted methyl or unsubstituted ethyl; Z is CR.sup.6, or N; R.sup.1 is hydrogen, or alkyl; R.sup.4, R.sup.5 and R.sup.6 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkenyl, or alkynyl.

A compound of formula: ##STR00001##
or its pharmaceutically acceptable salt. L is NR.sup.2R.sup.3, SR.sup.7, SO.sub.2R.sup.8, alkyl, or alkenyl; R.sup.2 is hydrogen, alkyl, alkenyl, or alkynyl; R.sup.3 is hydrogen, alkyl, alkenyl, alkynyl; R.sup.7 is hydrogen, alkyl, alkenyl, or alkynyl; R.sup.8 is hydrogen, alkyl, alkenyl, or alkynyl, provided that R.sup.8 is not unsubstituted methyl or trifluoromethyl; Y is alkyl, alkenyl, alkynyl, aryl, provided that Y is not unsubstituted methyl or unsubstituted ethyl; Z is CR.sup.6, or N; R.sup.1 is hydrogen, or alkyl; R.sup.4, R.sup.5 and R.sup.6 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkenyl, or alkynyl.

Compounds of formula (I):

##STR00001##

as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

Compounds of formula (I):

##STR00001##

as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof: ##STR00001##

The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof: ##STR00001##

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.

The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.